Company Overview and News
KUALA LUMPUR (July 18): A homegrown Singaporean company that owns one of the financial center’s three seawater desalination plants is struggling to stay afloat. Whether Hyflux Ltd. sinks or swims will matter to creditors and shareholders. The strategic stakes, though, are far higher.
1155 MLYBY MLYNF KPLIF
(July 18): A homegrown Singaporean company that owns one of the financial center’s three seawater desalination plants is struggling to stay afloat. Whether Hyflux Ltd. sinks or swims will matter to creditors and shareholders. The strategic stakes, though, are far higher.
1155 MLYBY MLYNF KPLIF
After the weekend’s football World Cup final that will see either France or Croatia emerge champions, investors will turn their attention to China’s second-quarter economic growth number, which will be out on Monday.
1155 MLYBY MLYNF 5021
(July 12): Most Southeast Asian stock markets edged higher on Thursday, with the Philippines touching a near one-month high and Indonesia extending gains for a fourth session, as broader Asian peers recovered slightly from the previous session's steep losses.
UOVEF PBLOF MLYBY MLYNF AYAAY 1295 U11 GIGNY 1155 G13 UOVEY GIGNF ALI AYAAF
KUALA LUMPUR (July 12): The FBM KLCI reversed its earlier losses and climbed 0.44% at midday break, tracking regional markets, lifted by gains including at banking heavyweights Malayan Banking Bhd and Pulic Bank Bhd.
PBLOF MLYBY SPMXF MLYNF BATS 4162 1295 7153 5168 1155 KLKBY 3204 2445 SPMXY 4456 3301 3867 7205 0026 1899 5819 HRGHY
IN May, Malayan Banking Bhd, the country’s largest financial services group, reached a new milestone, hitting RM100 billion in market capitalisation. It was an impressive, albeit brief, achievement as its market cap is now at RM97.83 billion, owing to skittish investor sentiment. Is it a good time to buy its shares, or those of CIMB, since both government-linked banks have taken a beating of late?
1155 1023 MLYBY MLYNF HYFXF HYFXY CIMDF
KUALA LUMPUR (July 11): The FBM KLCI retreated in early trade this morning, tracking regional markets as the U.S. rattled markets with its decision to impose additional tariffs on China imports.
1155 SPMXY MLYBY SPMXF 6888 MLYNF BATS 4162 AXXTF GEBHF
KUALA LUMPUR (July 9): Sapura Energy Bhd's share price jumped 2.5% or 1.5 sen to 62 sen on news that its exploration and production arm will be listed on the Australian stock exchange.
1155 MLYBY MLYNF
KUALA LUMPUR: Most analysts that cover Malaysian equities view the selldown seen in the last two months on the FBM KLCI, as buying opportunities for long-term investors amid the uncertainties triggered by US tariffs on China that kicked in last Friday, as well as the new direction under the Pakatan Harapan government.
1155 4863 5347 MLYBY TNABY MLYNF MYTEF TNABF BSMAF 1818
Top stocks: A man watches trading boards at a private stock market gallery in Kuala Lumpur. High on MIDF Research’s list of recommendations for the third quarter are Bermaz Auto Bhd and Malayan Banking Bhd, as well as Mah Sing Group Bhd and UOA Develeopment Bhd. — AP
1155 1023 MLYBY MLYNF 8583 CIMDF
KUALA LUMPUR: Malayan Banking Bhd (Maybank) is partnering Credit Guarantee Corp Malaysia Bhd (CGC) to provide up to RM2 billion financing to small- and medium-sized enterprises (SMEs) via the latter’s portfolio guarantee (PG) scheme.
1155 MLYBY MLYNF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET